Last reviewed · How we verify
A51R2
A51R2 is an investigational drug with unknown mechanism of action.
At a glance
| Generic name | A51R2 |
|---|---|
| Sponsor | AJU Pharm Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Due to limited information, the exact mechanism of A51R2 is not well understood.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients (PHASE3)
- Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults (PHASE1)
- The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A51R2 CI brief — competitive landscape report
- A51R2 updates RSS · CI watch RSS
- AJU Pharm Co., Ltd. portfolio CI